PREdiction of CEphalosporinase Producing Enterobacteria During Ventilator-associated Pneumonia for Therapeutic Stewardship

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05486130

Enrollment

345

Registered

2022-08-03

Start date

2022-07-18

Completion date

2023-12-31

Last updated

2023-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator Associated Pneumonia

Brief summary

Ventilator-associated pneumonia is the leading cause of nosocomial infection in the ICU. Cephalosporinase-producing Enterobacteriaceae have an increasing incidence. Infections in cephalosporinase-producing patients require the use of Cefepime during probabilistic antibiotic therapy, the repeated use of which will lead to a significant risk of selection of resistant mutants. The involvement of cephalosporinases being infrequent, the prediction of their presence during a VAP would make it possible to reduce the consumption of Cefepime and thus to take part in the prevention of selection of bacterial mutants resistant to beta-lactams. The main objective of the research is to determine the risk factors for the involvement of cephalosporinase-producing enterobacteria during episodes of ventilator-associated pneumonia (VAP) in hospitalized patients. The secondary objectives are to describe the epidemiology of cephalosporinase-producing enterobacteria in the ICU and to compare the risk factors for the presence of a cephalosporinase-producing germ not without its production being derepressed with those present in situations of cephalosporinase derepression.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient 18 years and older * Patient on mechanical ventilation for more than 48 hours * Patient with a diagnosis of ventilator-associated lung disease during management according to American Thoracic Society criteria * French speaking patient

Exclusion criteria

* Tracheostomized patient at the time of inclusion * Limitation of therapies before inclusion in the study * Patient under guardianship or curatorship * Patient deprived of liberty * Patient under court protection * Patient objecting to the use of his/her data for this research

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of cephalosporinase-producing enterobacteria during episodes of ventilator-associated pneumonia	1 month	This outcome corresponds to the the number of ventilator-associated pneumonias involving cephalosporinase-producing enterobacteria.

Secondary

Measure	Time frame	Description
Epidemiology of cephalosporinase-carrying enterobacteria in the ICU	1 month	This outcome corresponds to the number of pathogens identified in ventilator-associated pneumonia.

Countries

France

Outcome results